ADVB (Advanced Biomed) EBIT: $-3.36 Mil (TTM As of Mar. 2026)


ADVB Advanced Biomed Inc ADVB
12 GF Score
Price $5.07
! 1 Warning Sign
View Full Analysis

What is Advanced Biomed EBIT?

Advanced Biomed ADVB +3.10% 12 EBIT is $-3.36 Mil as of Mar. 2026. GuruFocus rates ADVB with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Advanced Biomed's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-0.49 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-3.36 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Advanced Biomed's annualized ROC % for the quarter that ended in Mar. 2026 was -30.48%. Advanced Biomed's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -264.15%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Advanced Biomed's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -57.83%.

Advanced Biomed  (NAS:ADVB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Advanced Biomed's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-2.08 * ( 1 - 0% )/( (7.012 + 6.636)/ 2 )
=-2.08/6.824
=-30.48 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=10.851 - 1.234 - ( 2.605 - max(0, 1.254 - 10.732+2.605))
=7.012

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=10.646 - 1.407 - ( 2.603 - max(0, 1.426 - 10.526+2.603))
=6.636

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Advanced Biomed's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.956/( ( (0.118 + max(0.711, 0)) + (0.118 + max(0.534, 0)) )/ 2 )
=-1.956/( ( 0.829 + 0.652 )/ 2 )
=-1.956/0.7405
=-264.15 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0.009 + 1.936) - (1.234 + 0 + 0)
=0.711

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0.009 + 1.932) - (1.407 + 0 + 0)
=0.534

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Advanced Biomed's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-3.356/5.803
=-57.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced Biomed EBIT Related Terms

Advanced Biomed EBIT Historical Data

* Premium members only.

The historical data trend for Advanced Biomed's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced Biomed EBIT Chart

Advanced Biomed Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
EBIT
-1.84 -2.37 -3.07 -2.54 -3.02

Advanced Biomed Quarterly Data
Jun21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.57 -1.95 -0.52 -0.40 -0.49

ADVB vs MBAI, XWEL, NDRA: EBIT Comparison

For the Diagnostics & Research subindustry, Advanced Biomed's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Advanced Biomed EV-to-EBIT vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Advanced Biomed's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Advanced Biomed's EV-to-EBIT falls into.


ADVB
12GF Score
Advanced Biomed Inc ADVB
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Advanced Biomed EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.36 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-3.36 Mil mean?
Advanced Biomed (ADVB) has a EBIT of $-3.36 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Advanced Biomed.
Is Advanced Biomed's EBIT too high?
Advanced Biomed's current EBIT is $-3.36 Mil. Overall, Advanced Biomed has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Advanced Biomed's EBIT compare to MBAI and XWEL?
Advanced Biomed's EBIT of $-3.36 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Diagnostics & Research company?
A good EBIT depends on the Medical Diagnostics & Research industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Advanced Biomed. Advanced Biomed's current EBIT is $-3.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Biomed stock overvalued right now?
Advanced Biomed (ADVB) has a current EBIT of $-3.36 Mil. The current EBIT is $-3.36 Mil. Advanced Biomed's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Advanced Biomed (ADVB), the current EBIT is $-3.36 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Advanced Biomed Business Description

Address No. 689-85 Xiaodong Road, Yongkang District, Tainan, TWN
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.
12GF Score

Get the complete analysis for ADVB

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.07
Price